Biogen, Inc. (BIIB)
$238.79
3.17 (1.35%)
BIIB Stock Quote Delayed 15 Minutes
Previous Close
$238.79
Market Cap
50.39B
PE Ratio
17.06
EPS
14
Volume (Avg. Vol.)
3.81M
Day's Range
234.30 - 242.21
52-Week Range
215.77 - 358.41
Dividend & Yield
N/A (N/A)
BIIB Stock Predictions, Articles, and Biogen, Inc. News
3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).
Biogen Earnings: BIIB Stock Surges on Big Q2 Earnings Beat
Biogen earnings for the second quarter of the year have BIIB stock heading higher on Tuesday thanks to a strong EPS and revenue beat.
MS Franchise, Spinraza Likely to Be Key Catalysts for Biogen Stock
The owners of Biogen stock will examine Biogen earnings to asss the progress that BIIB is making in key areas, including Ms and Spinraza.
Nasdaq Today: Biotech Wrecked; Buy Microsoft?
Investors saw new highs in the Nasdaq today, but the index finished slightly lower on the day. Here's what we're watching now.
Nasdaq Today: Apple Loses Ive and the Nasdaq’s Q3 Outlook
The second quarter is the books, at least as far as the stock market is concerned. Here's a look at the Nasdaq today.
Nasdaq Today: Hard to Keep Track of the Losers
Biotech rallied on a $63 billion deal between AbbVie and Allergan. But other than that, it was a tough day for the Nasdaq today.
Nasdaq Today: Maintaining Altitude Amid Uncertainty
PayPal, Slack, and chip stocks like AMD and Nvidia, Micron and Nio were all big movers in the Nasdaq today. Get the scoop, now.
Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder
Zynerba landed a new patent for its Zygel product to use cannabidiol as a treatment for Autism Spectrum Disorder, sending ZYNE stock ripping.
Biogen Earnings: BIIB Stock Slips Despite Q1 Beat
Biogen earnings for the first quarter of 2019 have BIIB stock down on Wednesday despite it beating it estimates for the period.
Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock
Smaller-capitalization biotechs can be riskier investments, but EXEL stock has more than just promise off and on the price chart and is readying to be purchased.
Is It Safe to Buy Biogen Stock Right Now?
Biogen stock is under big-time pressure, with BIIB falling more than 30% over the past two trading sessions. Is the coast clear yet?
Biogen Stock Fell Too Far on Unfortunate News
BIIB stopping its Alzheimer's trials hurt. But for long-term investors, the dip has opened up an opportunity in Biogen stock
3 Big Stock Charts for Friday: AT&T, Morgan Stanley and Lowe’s Companies
The stock charts of T, LOW and MS merit some close technical scrutiny before the trading week comes to a close. Here's what you need to know.
Biogen News: BIIB Stock Plummets on Alzheimer’s Drug Failure
Biogen news about the company's decision to discontinue two Phase 3 Alzheimer’s drug studies is hitting BIIB stock hard on Thursday.
NITE, BIIB: Nightstar Therapeutics Stock Soars on Biogen Buy
Nightstar Therapeutics stock was soaring on Monday following news that Biogen (BIIB) is acquiring the company for $877 million.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
D
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!
